Table 1. Clinical features of AIEOP and BFM-G study cohort patients positive or negative for CRLF2 overexpression.

Characteristics	AIEOP					BFM-G
	P-value	CRLF2-low		CRLF2-high		P-value	CRLF2-low		CRLF2-high
		N	%	N	%		N	%	N	%
All patients		103	100	17	100		80	100	12	100
Gender	0.40					0.99
Male		82	79.6	12	70.6		62	77.5	9	75.0
Female		21	20.4	5	29.4		18	22.5	3	25.0
Age	0.48					0.15
1-5 Yrs		38	36.9	5	29.4		23	28.8	1	8.3
6-9 Yrs		22	21.4	4	23.5		24	30.0	3	25.0
10-14 Yrs		36	35.0	5	29.4		24	30.0	4	33.3
15-17 Yrs		7	6.8	3	17.6		9	11.3	4	33.3
WBC (X1000/ul)	0.21					0.42
<20		26	25.2	1	5.9		6	7.5	2	16.7
20-100		34	33.0	7	41.2		27	33.8	5	41.7
≥ 100		43	41.7	9	52.9		47	58.8	5	41.7
Immunophenotype	0.93					<0.001
Early-T		30	29.1	6	35.3		8	10.0	6	50.0
Thym		55	53.4	9	52.9		62	77.5	4	33.3
Mature T		13	12.6	2	11.8		9	11.3	2	16.7
Not specified		5	4.9	0	0		1	1.3	0	0
Predn. Response	0.02					0.09
Good		70	68.0	7	41.2		53	66.3	4	33.3
Poor		31	30.1	10	58.8		27	33.8	7	58.3
Unknown		2	1.9	0	0		0	0	1	8.3
MRD	0.73					0.88
SR		15	14.6	1	5.9		10	12.5	1	8.3
MR		35	34.0	5	29.4		51	63.8	5	41.7
HR		18	17.5	3	17.6		13	16.3	2	16.7
Unknown		35	34.0	8	47.1		6	7.5	4	33.3
Final Risk	0.05					0.11
no-HR		62	60.2	6	35.3		49	61.3	4	33.3
HR		41	39.8	11	64.7		31	38.8	8	66.7
P2RY8-CRLF2	-					-
No		90	87.4	16	94.1		78	97.5	12	100
Yes		0	0	0	0		0	0	0	0
Unknown		13	12.6	1	5.9		2	2.5	0	0

WBC, White Blood Cell count; MRD, Minimal Residual Disease; HR, High Risk; MR, Medium Risk; SR, Standard Risk.